Lupin gets warning letter from USFDA for Tarapur facility

29 Sep 2022 Evaluate

Lupin has received a warning letter from the USFDA for the Company’s Tarapur, Maharashtra (India) facility. The USFDA had inspected the Lupin Tarapur site from March 22, 2022 to April 4, 2022. The Company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility.

The company is committed to addressing the concerns raised by the USFDA and will work with the USFDA to resolve these issues at the earliest. The company upholds quality and compliance issues with utmost importance and remain committed to be compliant with CGMP quality standards across all its facilities.

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2151.05 19.25 (0.90%)
30-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1595.00
Dr. Reddys Lab 1218.40
Cipla 1323.95
Zydus Lifesciences 885.20
Lupin 2151.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×